VERU
Veru·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 2
Ample Liquidity
Low Beta
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VERU
Veru Inc.
A biopharmaceutical company that developing novel medicines for COVID-19 and other viral ARDS-related diseases and oncology
2916 N. Miami Avenue, Suite 1000, Miami, Florida 33127
--
Veru Inc., founded in 1971. It is a late-stage clinical biopharmaceutical company focusing on the development of new drugs for the treatment of metabolic diseases, oncology, and ARDS. The company's drug development program includes two late-stage new chemical entities, enobosarm and sabizabulin.
Earnings Call
Q3/2025
Estimate EPS-0.05
Actual EPS-0.5
Estimate Revenue--
Actual Revenue0
Veru's Q3 2025 Earnings Call: Unpacking Key Contradictions in Phase III Trial Costs and Enobosarm's Safety Profile
Aug 12,2025 01:03
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
VERU has released its 2025 Q3 earnings. EPS was reported at -0.5, versus the expected -0.05, missing expectations. The chart below visualizes how VERU has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
